Press release
United States C-Reactive Protein Test (CRP) Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities
C-Reactive Protein Test (CRP) Market
The Global C - Reactive Protein Test (CRP) Market is estimated to reach at a CAGR of 1.8% during the forecast period (2023-2030).
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/c-reactive-protein-test-market?sb
Key Development:
United States: Recent Industry & Clinical Developments
✅ In February 2026, a comprehensive analysis revealed that elevated pre‐procedural C‐reactive protein levels significantly predict carotid and intracranial artery restenosis post‐revascularization, suggesting CRP's expanding role in vascular risk assessment and procedural prognosis.
✅ In January 2026, a comparative diagnostic study showed that procalcitonin outperformed CRP in detecting bloodstream infections in febrile neutropenic pediatric cancer patients, prompting discussions on biomarker selection in clinical settings and refined infection diagnostics.
✅ In December 2025, researchers developed and validated a multiplex fluorescent immunochromatographic strip capable of simultaneously quantifying hs‐CRP alongside MMP‐9 and LP‐PLA2, enabling rapid, sensitive, point‐of‐care inflammation profiling.
✅ In December 2025, market intelligence reports highlighted heightened investment and innovation in CRP diagnostics, underlining expanding adoption of high‐sensitivity CRP tests and supporting advanced clinical deployment in inflammatory and cardiovascular assessment.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=c-reactive-protein-test-market
Japan: Recent Industry & Clinical Developments
✅ In February 2026, the association between elevated CRP and vascular disease complications was confirmed in systematic research, reinforcing the test's clinical utility across diverse populations including Asian cohorts and emphasizing inflammation monitoring in stroke risk management.
✅ In January 2026, comparative infection biomarker research highlighted limitations of CRP versus procalcitonin for certain clinical diagnostics, prompting Japanese healthcare providers to refine biomarker protocols for accurate infection diagnosis in high‐need settings.
✅ In December 2025, the multiplex immunochromatographic strip technique incorporating hs‐CRP was validated, offering potential for rapid, onsite use in clinical environments throughout Asia including Japan to streamline inflammatory marker panels.
✅ In December 2025, strategic market insights pointed to increased CRP diagnostics integration in broader healthcare pipelines, with implications for Japanese diagnostics manufacturers exploring point‐of‐care and high‐sensitivity CRP assays.
Key Players:
=> Abbott Laboratories, F. Hoffmann-La Roche AG, Merck KGaA, Randox Laboratories Ltd., BODITECH MED INC., Abaxis, Inc., Thermo Fisher Scientific, Inc., Siemens, Laboratory Corporation of America Holdings, and Beckman Coulter Inc. (Danaher Corporation).
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/c-reactive-protein-test-market?sb
Key Segments:
By Assay Type
Immunoturbidimetric Assay leads with 28% share, driven by its rapid results, high accuracy, and cost-effectiveness in clinical and diagnostic applications.
ELISA captures 25% share, supported by high sensitivity, broad disease detection capabilities, and extensive laboratory adoption.
Clinical Assays hold 18%, reflecting rising demand for routine patient monitoring and point-of-care testing.
Nonclinical Assays account for 10%, mainly in research and pharmaceutical development.
Chemiluminescence Immunoassay represents 12%, driven by automation, high throughput, and adoption in advanced laboratories.
Others hold 7%, including emerging assay technologies and hybrid methods.
By Detection Type
hs-CRP (High-Sensitivity C-Reactive Protein) leads with 35% share, driven by cardiovascular disease risk assessment and preventive healthcare initiatives.
cCRP (Conventional CRP) accounts for 28%, reflecting its widespread use in standard inflammation monitoring.
Conventional CRP holds 25%, primarily for general clinical diagnostics and routine tests.
Others represent 12%, including novel detection methods and multiplex assays.
By Disease Area
Cardiovascular Diseases dominate with 30% share, due to the strong correlation between CRP levels and heart disease risk.
Cancer captures 18%, reflecting growing research and clinical applications in oncology diagnostics.
Rheumatoid Arthritis holds 12%, driven by increasing prevalence and the need for inflammation monitoring.
Inflammatory Bowel Disease represents 10%, supported by rising incidence rates and chronic disease management.
Endometriosis & Lupus account for 8%, reflecting adoption in specialized diagnostics.
Others hold 22%, covering additional inflammatory and autoimmune conditions.
By End-User
Clinics lead with 28% share, due to routine testing and preventive healthcare initiatives.
Hospitals capture 25%, driven by inpatient diagnostics and advanced laboratory integration.
Laboratories hold 22%, reflecting adoption in research, pharmaceutical, and contract lab services.
Diagnostic Centers account for 15%, primarily for outpatient and specialized testing.
Others represent 10%, including academic and private research setups.
By Region
North America dominates with 35% share, fueled by advanced diagnostic infrastructure, preventive healthcare focus, and strong adoption of hs-CRP assays.
Europe captures 28%, supported by growing cardiovascular and oncology testing initiatives.
Asia Pacific holds 20%, driven by expanding healthcare infrastructure and increasing cardiovascular disease awareness.
Latin America accounts for 10%, reflecting gradual adoption of advanced CRP assays.
Middle East & Africa represent 7%, driven by emerging diagnostic centers and increasing healthcare investments.
Outlook & Opportunity Analysis (2023-2030)
The CRP assay market is projected to grow steadily, driven by increasing cardiovascular disease prevalence, rising awareness of inflammatory conditions, and adoption of advanced diagnostic platforms. Key opportunities exist in hs-CRP testing, chemiluminescence assays, and expansion in emerging regions, particularly Asia Pacific and Latin America.
FAQ
Q: What is the growth rate of the C - Reactive Protein Test (CRP) Market?
A: The market is projected to expand at a compound annual growth rate (CAGR) of 1.8% during the forecast period from 2023 to 2030.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States C-Reactive Protein Test (CRP) Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities here
News-ID: 4409716 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Intelligent Emergency Response Systems and Infrastructure Market Rises as AI Dis …
The global Intelligent Emergency Response Systems and Infrastructure (IRSI) market was valued at US$ 1.3 billion in 2022 and is projected to reach US$ 2.1 billion by 2031, growing at a CAGR of 6.1% during the forecast period from 2024 to 2031. Market growth is driven by increasing investments in smart public safety infrastructure, AI-powered emergency response systems, and the rising need for disaster preparedness and real-time incident management.The Intelligent…
Anti-Senescence Therapeutics Market Moves From Longevity Hype Toward Biomarker-L …
The global anti-senescence therapeutics market was valued at USD 33.03 billion in 2025 and is projected to reach USD 53.39 billion by 2033, growing at a CAGR of 6.7% during the forecast period from 2026 to 2033. Market growth is driven by increasing investments in longevity research, rising prevalence of age-related diseases, and advancements in regenerative medicine and senolytic therapies. The Anti-Senescence Therapeutics Market is entering a new phase of…
Molecular Biosensors Market Accelerates as Point-of-Care Testing Moves Toward Fa …
The global Molecular Biosensors Market was valued at USD 30.80 billion in 2024, increased to USD 33.55 billion in 2025, and is estimated to reach USD 36.55 billion in 2026. The market is projected to grow to USD 56.04 billion by 2031, registering a CAGR of 8.93% during the forecast period from 2026 to 2031. These advanced sensing technologies combine molecular recognition with highly sensitive detection systems, enabling clinicians to…
ECG Patches and Holter Monitor Market Expands as Remote Cardiac Monitoring Shift …
The Global ECG Patches and Holter Monitor Market reached US$ 1,864.54 million in 2024 and is projected to grow to US$ 5,950.62 million by 2033, expanding at a CAGR of 13.7% during the forecast period (2025-2033). This robust growth reflects the increasing shift from short-term, wearable monitoring solutions that enable earlier detection of arrhythmias and other heart rhythm disorders. Advances in wearable ECG patches, cloud-connected monitoring platforms, and AI-assisted…
More Releases for CRP
Digitalization of the Product in Additive Manufacturing: CRP Group Presents CRP …
CRP Group launches CRP UniqTrust. Based in Modena, in the heart of Italy's Motor Valley, CRP Group is an international hub for CNC machining, metal and Windform® techno-polymer additive manufacturing.
Founded in 1970 as a specialist in high-precision CNC machining for motorsport, CRP Group has since expanded its expertise, technologies and sectors, adding metal additive manufacturing (DMLS) and 3D printing (SLS) in proprietary Windform® composites alongside CNC machining. As a manufacturing…
Finalized the ITT investment in CRP Technology and CRP USA
Modena, Italy, June 16th, 2022 - 3D printing leading companies CRP Technology and CRP USA have signed an investment agreement with ITT Inc., a diversified leading manufacturer of highly engineered critical components and customized technology solutions headquartered in Stamford, Connecticut (USA) and present in more than 35 countries.
According to the operation, ITT Inc. becomes part of the shareholder structure of CRP Technology and CRP USA, in line with its business…
CRP USA is AS9100 certified
CRP USA, pioneering company in the fields of Additive Manufacturing and high performance composite materials, announced it has recently achieved AS9100 Rev. D certification for the manufacture of 3D printed aerospace products from its customer's component design data.
AS9100 Rev. D certification signifies CRP USA’s ongoing commitment to meeting and exceeding increasingly stringent industry requirements for aerospace related products.
"We have taken our expertise in Additive Manufacturing solutions to new heights to…
CRP Technology shines at Sachsenring racetrack
Positive debut for the Italian-based companies and Energica’s technological partners for MotoE
CRP Technology and CRP Meccanica made their debut at Sachsenring racetrack during the inaugural weekend of MotoE (5 – 7 July 2019) as Energica technological partners.
The series had been stopped due to the Jerez fire but thanks to the hard work of Energica team and the partners involved, all Ego Corsa motorcycles were rebuilt in less than three months.
The…
CRP Technology is part of ARTES 4.0
CRP's cutting-edge AM technologies at the service of the most innovative projects in the field of Advanced Robotics
CRP Technology participates as an affiliated member to ARTES 4.0 association (Advanced Robotics and enabling digital TEchnologies & Systems 4.0).
The new born association leads the homonymous Competence Center coordinated by the Scuola Superiore Sant’Anna, and it is characterized as a partnership that connect universities, research institutes and companies focused on innovation.
ARTES 4.0 Competence…
MotoE™ ready to race thanks to CRP Meccanica and CRP Technology
Preparations are in progress for the resumption of the activities of the FIM Enel MotoE ™ World Cup after the setback last March, when a fire in Jerez destroyed much of the material for the MotoE™ , Ego Corsa machines included.
CRP Technology and CRP Meccanica did not fail to give Energica (the FIM Enel MotoE ™ World Cup single manufacturer) their support on a par with the commitment made…
